Avid Bioservices Inc (CDMO)

[pphmtoolong]

Peregrine management's stubbornness might make its taken-for-granted shareholders rich. Doesn't look like it now, but this could change in the next few weeks/months.

They have stubbornly pushed Bavi in the labs, in the clinics, in the seminars, etc. They just keep pushing it forward. Anyone who disputes this is not paying attention. Despite the CSM screw up, management stubbornly refused defeat, resurrected the data and convinced the FDA to green light the pivotal, Phase III Sunrise trial. A virtuoso performance. An amazing achievement. Stubbornness can be a great virtue.


They stubbornly refuse to loosen their grasp on the IP pipeline. No sharing with a partner, no sharing with a lender, no sharing with anybody. Many not happy with this approach. Still stubbornly refusing to sell the IP cheaply despite the prospect of ATM dilution. Management has reached this late stage with the IP ownership intact. If the anti-PS platform and Bavi are as valuable as they think, all the painful dilution over recent years may be well rewarded by Bavi commercialization.

They stubbornly keep pushing Avid to grow and make more revenue, despite their obvious focus on Bavi. While not the money machine we would all like, Avid does continue to grow at a respectable rate.

While Peregrine's stubborn failure to share information we shareholders crave is frustrating, clearly their stubbornness is pushing the company toward a potential big winner in Bavi commercialization.

We'll see. Soon, weeks to months, not years.

GLTA, Especially Bavi-Arm Sunrise Patients,

Paul